Market open
ImmuCell/$ICCC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmuCell
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Ticker
$ICCC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
72
Website
ImmuCell Metrics
BasicAdvanced
$48M
-
-$0.26
0.39
-
Price and volume
Market cap
$48M
Beta
0.39
52-week high
$5.72
52-week low
$4.28
Financial strength
Current ratio
3.409
Quick ratio
1.716
Long term debt to equity
47.86
Total debt to equity
54.872
Interest coverage (TTM)
-2.17%
Management effectiveness
Return on assets (TTM)
-1.73%
Return on equity (TTM)
-8.39%
Valuation
Price to revenue (TTM)
1.659
Price to book
1.76
Price to tangible book (TTM)
1.76
Price to free cash flow (TTM)
-407.545
Growth
Revenue change (TTM)
51.63%
Earnings per share change (TTM)
-64.79%
3-year revenue growth (CAGR)
11.25%
3-year earnings per share growth (CAGR)
194.77%
ImmuCell News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ImmuCell stock?
ImmuCell (ICCC) has a market cap of $48M as of April 08, 2025.
What is the P/E ratio for ImmuCell stock?
The price to earnings (P/E) ratio for ImmuCell (ICCC) stock is 0 as of April 08, 2025.
Does ImmuCell stock pay dividends?
No, ImmuCell (ICCC) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next ImmuCell dividend payment date?
ImmuCell (ICCC) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmuCell?
ImmuCell (ICCC) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.